Torky Magda A, Al Zafiri Yousif A, Hagras Sherein M, Khattab Abeer M, Bassiouny Rania M, Mokbel Tharwat H
Department of Ophthalmology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Department of Ophthalmology, Dar AlShifa Hospital, Hawally City 30000, Kuwait.
Int J Ophthalmol. 2019 Apr 18;12(4):597-602. doi: 10.18240/ijo.2019.04.12. eCollection 2019.
To evaluate the safety and the efficacy of the ultrasound ciliary plasty (UCP) on the intraocular pressure (IOP) control in glaucomatous eyes without previous glaucoma surgery.
A retrospective study included patients with primary and secondary glaucoma who underwent UCP in Dar AlShifa Hospital, Kuwait between January 2017 to June 2018. High-intensity focused ultrasound procedures were performed under peribulbar anesthesia using the 2 generation probe with 8s duration of each of the 6 shots. Complete ophthalmologic examinations were scheduled pre-treatment, and at 1d, 1wk, 1, 3, 6 and 12mo post-treatment. Primary outcomes were the IOP reduction and success rates at 12mo, while the secondary outcomes were the occurrence of vision threatening complications and visual acuity.
The records of 62 eyes of 62 patients were analyzed with mean age of 63.8y (67.7% males). There was statistically significant reduction in the mean IOP from 35.2±8.3 mm Hg before treatment to 20.6±8.7 mm Hg at 12 month (<0.0005) with a mean percentage IOP reduction of 42.3% with significant reduction in the mean number of antiglaucomatous drugs from 3.2±0.4 before treatment to 2.1±1.02 at 12mo (<0.0005). Qualified success was achieved in 77.4% of eyes at 12mo. No major intra- or post-treatment complications were reported.
Second-generation UCP prove to be effective in reducing IOP in naive glaucoma patients with lower success rates in cases of neovascular and uveitic glaucomas.
评估超声睫状体成形术(UCP)对未经青光眼手术的青光眼患者眼压(IOP)控制的安全性和有效性。
一项回顾性研究纳入了2017年1月至2018年6月期间在科威特达尔希法医院接受UCP的原发性和继发性青光眼患者。使用第二代探头在球周麻醉下进行高强度聚焦超声操作,每次6次射击,每次持续8秒。在治疗前、治疗后1天、1周、1个月、3个月、6个月和12个月安排完整的眼科检查。主要结局是12个月时的眼压降低和成功率,次要结局是威胁视力并发症的发生和视力。
分析了62例患者62只眼的记录,平均年龄63.8岁(男性占67.7%)。平均眼压从治疗前的35.2±8.3 mmHg有统计学意义地降低到12个月时的20.6±8.7 mmHg(<0.0005),平均眼压降低百分比为42.3%,抗青光眼药物的平均数量从治疗前的3.2±0.4有显著降低到12个月时的2.1±1.02(<0.0005)。12个月时77.4%的眼睛取得了合格的成功率。未报告主要的治疗中或治疗后并发症。
第二代UCP被证明在降低初发青光眼患者眼压方面有效,在新生血管性青光眼和葡萄膜炎性青光眼病例中成功率较低。